MetaCap

Maze Therapeutics Inc. (MAZE)

NASDAQ: MAZEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

31.37-1.06 (-3.27%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MAZE stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.62
52-week range
21.95 – 53.65
Day range
30.88 – 32.80
Volume / Avg
818.93K / 737.14K
Beta
—

52-week range

$21.95$53.65

MAZE stock today

On Nov 20, MAZE ended the session at $31.37, shedding $1.06 (3.27%), versus the S&P 500's 3.70% decline. Shares are 41.5% below their 52-week high of $53.65, set on Mar 16, 2026 and 42.9% above the 52-week low of $21.95, in the middle of the past year's range. MAZE is down 24.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 13.5%.

Maze Therapeutics has posted a net loss over the last twelve months (EPS of -$2.62), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Maze Therapeutics

Company profile

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D.
Headquarters
South San Francisco, CA
Employees
141
IPO year
2025
Website
mazetx.com

Financial highlights

Full financials

Maze Therapeutics reported a net loss of $131.1 million, compared with net income of $52.2 million a year earlier. Diluted earnings per share came in at -$3.05, down from $1.25.

Maze Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024
Revenue—$167.50M
Growth——
Net income$-131.12M$52.23M
EPS (diluted)$-3.05$1.25

Analyst forecast

Forecast

Consensus (14 analysts)

strong_buy

Avg. price target

$62.46+99.11%

  • Strong buy 1
  • Buy 13
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $46.00High $110.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.79 vs $-0.78
Surprise
-1.28%

MAZE news

All MAZE news

Maze Therapeutics peers

Health Care sector
MAZE peer companies
CompanyPrice% ChgMarket capCompare
LYCALycia Therapeutics Inc.33.07+4.09%$1.72Bvs MAZE
REPLReplimune Group Inc.19.07-0.83%$1.81Bvs MAZE
COAGHemab Therapeutics Holdings Inc.39.29-1.43%$1.84Bvs MAZE
BCRXBioCryst Pharmaceuticals Inc.7.22-1.37%$1.86Bvs MAZE
VIRVir Biotechnology Inc.8.39-5.41%$1.56Bvs MAZE
RXRXRecursion Pharmaceuticals Inc. Class A2.45-9.93%$1.53Bvs MAZE
ALVOAlvotech4.12-3.96%$1.47Bvs MAZE
WWBWindward Bio Group AG24.29+1.15%$1.45Bvs MAZE

Indexes, lists and sector

Maze Therapeutics stock FAQ

What is Maze Therapeutics's stock price today?

MAZE last traded at $31.37 as of Nov 20, 4:00 PM EST, down 3.27% on the day. Prices are delayed at least 15 minutes.

Who is Maze Therapeutics's CEO?

Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. is the chief executive officer of Maze Therapeutics Inc., which has about 141 employees.

What is the MAZE 52-week high?

The 52-week high for MAZE is $53.65 and the 52-week low is $21.95. The stock is currently 41.5% below its high.

Compare MAZE